NAMPT Inhibitors Pipeline Analysis Market (Phase: Phase II, Phase I/II, Phase I, and Preclinical; and Type of Molecule: Small Molecules and Biologics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2032

The global nampt inhibitors pipeline analysis market size was valued at USD 300.9 million in 2022 and is predicted to be worth USD 1.90 billion by 2032, with a CAGR of 4.2% from 2023 to 2032. 

Key Pointers:

• In terms of phase, NAMPT inhibitors have been segregated into phase II, phase I/II, phase I, and preclinical.
• Based on application, the NAMPT inhibitors market has been bifurcated into oncology and others (respiratory and neurology disorders). Oncology was the most promising segment in 2022.
• In terms of type of molecule, NAMPT inhibitors have been split into small molecules and biologics.
• The North American region is anticipated to considerably contribute to market growth from 2023 to 2032.
• The Asia Pacific region will grow at the fastest CAGR from 2023 to 2032.

Nicotinamide adenine dinucleotide (NAD) is a metabolite, which is an important second messenger and cofactor for a number of cellular processes such as metabolism and genomic stability, which are necessary for survival. Body cells preserve adequate NAD levels with the help of multiple enzymatic pathways. NAMPT enzyme is the rate-limiting enzyme of the primary pathway for sustaining cellular NAD levels. The regulator function of NAMPT enzyme has made it an essential target for drug discovery efforts intended to interfere with cancer metabolism.

NAMPT inhibitors are characterized not only by cytochrome inhibition, but also by the formation of toxic metabolites and scarce aqueous solubility. Nicotinamide phosphoribosyltransferase is expressed relative to non-cancerous cells in carcinomas, lymphomas and astrocytomas. Furthermore, NAMPT inhibitor activities have shown anti-cancerous properties in several models of organ-specific cancers.

Rise in prevalence and the incidence rate of cancer, including colorectal, ovarian, prostate, breast, lung, and kidney, is driving patient burden. This is likely to augment the demand for NAMPT inhibitors for cancer treatment across the globe.

According to the National Cancer Institute (NIH), around 1,806,590 cancer cases were diagnosed in the U.S. in 2020. Prostate, lung, and colorectal cancers accounted for 43.0% of the total cancer cases in men. The number of people living with cancer stood at around 2.25 million in India in 2018. Every year, around 1,157,294 new cancer patients are diagnosed in the country. Furthermore, cancer-related deaths are projected to be around 784,821 every year.

Around 16,850 children and adolescents were diagnosed with cancer in the U.S. in 2020, while US$ 150.8 Bn is the projected national expenditure on cancer care. Around 628,519 new cancer cases were reported in Germany in 2020, with 344,451 cancer cases diagnosed in men and 284,068 in women. More than 60% of the world’s new cancer cases are recorded in Africa, Asia, and Central and South America; around 70% of the total cancer deaths across the globe occur in these regions.

NAMPT Inhibitors Pipeline Analysis Market Segmentation

NAMPT Inhibitors Pipeline Analysis Market Key Players And Regions